In brief: Living Cell Technologies, Phosphagenics, Rockeby, Antisense, Prima, Proteome Systems
Friday, 14 October, 2005
Living Cell Technologies (ASX:LCT) has appointed US based neuroscientist Dr Dwaine F Emerich as chief scientific officer of LCT BioPharma. He has been LCT's US vice-president of research since 2003, joining the company from Sertoli Technologies.
Phosphagenics' (ASX:POH) has appointed Dr Esra Ogru, vice-president of research & development, to the board of directors.
Rockeby biomed (ASX:RBY) has signed a five-year exclusive agreement with Pharmaplan South Africa for the marketing and distribution of CanDia5, its point-of-care test kit to detect Vulvo-Vaginal Candidiasis, in South Africa. The sales of CanDia5 through Pharmaplan are expected to generate revenue for Rockeby in the current financial year.
Antisense Therapeutics' (ASX:ANP) development director Dr Jega Iswaran has resigned. The company's clinical development program will now be overseen by development manager, Nuket Desem.
Prima Biomed (ASX:PRR) has completed inital recruitment of its phase IIa clinical trial in ovarian cancer at the Austin Hospital in Melbourne.
Proteome Systems (ASX:PXL) has signed a heads of agreement with Prince Henry's Institute Medical Research (PHIMR) to combine their IP to develop an ovarian cancer diagnostic test.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
